Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy

• Published in: Cancers Vol. 15; no. 6; p. 1834
• Main Authors: Oura, Kyoko, Morishita, Asahiro, Tani, Joji, Nomura, Takako, Manabe, Takushi, Takuma, Kei, Nakahara, Mai, Tadokoro, Tomoko, Fujita, Koji, Mimura, Shima, Sanomura, Takayuki, Nishiyama, Yoshihiro, Masaki, Tsutomu
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18-03-2023; MDPI
• Subjects: Adverse events; Atrophy, Muscular; Cancer; Cancer therapies; Care and treatment; Catheters; Chemotherapy; Cholangiocarcinoma; Clinical outcomes; Computed tomography; Drug dosages; Health aspects; Hepatocellular carcinoma; Hepatoma; Liver; Liver cancer; Liver diseases; Lymphatic system; Medical prognosis; Metastasis; Methods; Multivariate analysis; Muscles; Musculoskeletal system; Nutritional status; Patient outcomes; Patients; Prognosis; Sarcopenia; Skeletal muscle; Survival; Tumors; Veins & arteries; Japan; psoas muscle; transcatheter arterial chemoembolization; clinical outcome; hepatic arterial infusion chemotherapy; skeletal muscle; prognosis; hepatocellular carcinoma; sarcopenia
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15061834

Sarcopenia-related factors, including the skeletal muscle index (SMI), are reportedly associated with prognosis in patients with hepatocellular carcinoma (HCC) receiving various treatments. However, there is no evidence relating to hepatic arterial infusion chemotherapy (HAIC). In this study, we investigated whether a low SMI was associated with worse clinical outcomes of HAIC. Seventy patients with advanced HCC were included. Clinical outcomes were compared between the decreased SMI (n = 27) and non-decreased SMI (n = 43) groups, which were classified according to changes in the SMI after 3 weeks of treatment. In the prognostic analysis, patients in the decreased SMI group had significantly shorter progression-free and overall survival (OS) than those in the non-decreased SMI group. In addition, poor nutritional status and liver function were associated with an immediate decrease in the SMI after HAIC. The therapeutic effect was worse in the decreased SMI group than in the non-decreased SMI group, although the incidence of adverse events did not significantly differ. In multivariate analysis, a decreased SMI at 3 weeks after HAIC was identified as a significant independent factor associated with OS. A decreased SMI in patients with advanced HCC undergoing HAIC was associated with poor prognosis. It is effective to monitor the SMI to evaluate general conditions and predict clinical outcomes.